UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Consider index investing for broad diversification and low costs after establishing risk tolerance and goals. This guide points to ideal moments.
13,296 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
An almost 12% jump in lantheus holdings stock popped last month left investors asking what lit the fuse. This article...
Rigetti Computing lives at the edge of technology and finance. This article breaks down the revenue puzzle, the risks...
Fastly stock already doubled this year, leaving many investors wondering if the rally can continue. This guide breaks...
A diversified quartet of high-yield ETFs aims to deliver monthly income above 6%. This piece breaks down how they wor...
Greg Abel has stepped into Berkshire Hathaway’s top role with a plan that blends steady operations with a measured ap...
A high-yield dividend stock jumped about 31% over three months. As March begins, investors must weigh income potentia...
Dollar General delivered strong Q4 numbers, yet the stock hasn’t taken off. This article breaks down what happened, w...
Former Indeed CEO Chris Hyams argues the real AI danger comes from the people steering the technology, not the code. ...
War-time disruption in the Middle East drives oil higher and pushes up consumer costs, threatening to accelerate infl...
In 2026, investors are focusing on profits, not just sales. This guide explains the walmart metric watch 2026 framewo...
Netflix has transformed how we watch TV, but investors are asking if the stock can reach $200. This article breaks do...